Four in five cases of disease are diagnosed when patients have scans for unrelated conditions or in emergency departments, ...

Basketball Hall of Famer Dwyane Wade talked for the first time yesterday about his surgery for kidney cancer in December 2023.

Dwyane Wade revealed on a podcast that he underwent surgery to remove a cancerous tumor and part of his kidney in December ...

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...